Please try another search
Verici Dx plc, develops of prognostic and diagnostic test for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company also develops Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. Verici Dx plc was incorporated in 2020 and is based in Penarth, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
David M. Rothstein | - | - | Member of Advisory Board |
Weiija Zhang | - | - | Member of Advisory Board |
Richard Formica | - | - | Member of Advisory Board |
Roslyn B. Mannon | - | - | Member of Advisory Board |
Lorenzo Giovanni Gallon | 60 | 2021 | Non-Executive Director & Chair of Science Advisory Board |
Sara Barrington | 57 | 2020 | CEO & Executive Director |
Anthony Dorling | - | - | Member of Advisory Board |
Philip O'Connell | - | - | Member of Advisory Board |
Julian Huw Baines | 60 | 2020 | Independent Non-Executive Chairman |
Ian James Carruthers | 73 | 2020 | Senior Independent Non-Executive Director |
James R. McCullough | 56 | 2020 | Independent Non-Executive Director |
Emilio D. Poggio | - | - | Member of Advisory Board |
Erik K. Lium | 56 | 2020 | Independent Non-Executive Director |
Peter Nickerson | - | - | Member of Advisory Board |
Kathryn Wood | - | - | Member of Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review